Immune therapy trial targets Virus-Linked liver tumors
NCT ID NCT03419481
Summary
This study tests the immunotherapy drug pembrolizumab in 30 patients with advanced liver cancer caused by chronic hepatitis B infection. Researchers will give the drug every three weeks and take tumor samples before and during treatment to study how the immune system responds. The main goals are to see if the treatment shrinks tumors safely and to understand immune changes that might predict who benefits most.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Clinical Oncology, Prince of Wales Hospital
Hong Kong, Hong Kong
Conditions
Explore the condition pages connected to this study.